Mi az ára Purple Biotech Ltd. (PPBT)

Purple Biotech Ltd. (PPBT) ára $0.00323826

Mi a Purple Biotech Ltd. (PPBT piaci tőkésítése)

Purple Biotech Ltd. piaci tőkésítése (PPBT) $104.81K

Purple Biotech Ltd. (PPBT) Ár és Piaci Kapitalizáció

Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.

A PPBT ára	B aktíva	A B piaci tőkésítése	Eredmények
$168,876 $104.81K	NVDA	$5.466T	+5,215,023,849.19%
$137,679 $104.81K	AAPL	$4.456T	+4,251,622,723.86%
$128,921 $104.81K	GOOG	$4.173T	+3,981,191,316.99%
$113,941 $104.81K	MSFT	$3.688T	+3,518,595,960.56%
$88,509.19 $104.81K	AMZN	$2.865T	+2,733,230,024.17%

A PPBT ára

B aktíva

A B piaci tőkésítése

Eredmények

$168,876 $104.81K